Skip to main content
Clinical Trials/NCT02704780
NCT02704780
Completed
Phase 2

Umbilical Vein Injection of 800µg Misoprostol Versus 400 µg Misoprostol in the Treatment of Retained Placenta: A Multicenter, Randomized Double Blind Controlled Trial

Hawler Medical University1 site in 1 country509 target enrollmentMarch 2016

Overview

Phase
Phase 2
Intervention
Misoprostol
Conditions
Postpartum Haemorrhage
Sponsor
Hawler Medical University
Enrollment
509
Locations
1
Primary Endpoint
Delivery of placenta after injection of of 400 Microgram intraumbilical misoprostol versus 800 microgram of misoprostol
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study evaluates intra umbilical vein injection of 800 µg versus 400 µg misoprostol for the treatment of retained placenta to reduce the need of manual removal of placenta under general anaesthesia

Detailed Description

The third stage of labor may be complicated by retained placenta, which may cause severe bleeding and infection, with a potentially fatal outcome. Manual removal of placenta is the current standard of management of retained placenta which usually requires general or regional anaesthesia at a hospital and it is an invasive procedure that may lead to bleeding, trauma and infection. Intraumbilical injection of uterotonic agent( misoprostol) is an easy, non invasive procedure. A randomized clinical trial are required to determine the difference between two doses of misoprostol 400 versus 800 micro gram for management of retained placenta

Registry
clinicaltrials.gov
Start Date
March 2016
End Date
February 14, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Shahla Alalaf

Professor Shahla K.Alalaf

Hawler Medical University

Eligibility Criteria

Inclusion Criteria

  • women with a singleton pregnancy, delivered vaginally
  • 28 weeks of gestation and more,
  • had a prolonged third stage of labor (more than 30 minutes) despite active management,
  • Haemodynamically stable and accept to participate in the trial

Exclusion Criteria

  • multiple pregnancies,
  • previous caesarean delivery,
  • haemodynamically instability, severe anaemia (haemoglobin concentration \<8 g/dL),
  • chorioamnionitis
  • Refused to participate in the trial

Arms & Interventions

400 Microgram Misoprostol

Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group

Intervention: Misoprostol

800 Microgram Misoprostol

Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group

Intervention: Misoprostol

Outcomes

Primary Outcomes

Delivery of placenta after injection of of 400 Microgram intraumbilical misoprostol versus 800 microgram of misoprostol

Time Frame: up to 30 minutes after intraumbilical injection

complete delivery of placenta after injection of intraumbilical misoprostol

Secondary Outcomes

  • side effects of misoprostol(up to 24 hours after delivery of placenta)
  • The amount of blood loss vaginally in both groups(up to 30 minutes after injection of placenta)
  • The time of delivery of placenta in both groups(up to 30 minutes after delivery of the placenta)

Study Sites (1)

Loading locations...

Similar Trials